Viking Therapeutics (NASDAQ:VKTX), often touted as an attractive obesity play, shed more than a third of its value this week ...

The drug, which is estimated to be taken by up to 750,000 people, is one of the country's most popular weight loss and ...

Robert F. Kennedy Jr.’s leadership at HHS sparks controversy as his vaccine agenda reshapes policy, regulation, and public health.

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

Eli Lilly and Company faces a pivotal period with the upcoming retirement of Anne White, a key neuroscience leader set for ...

Thermo Fisher Scientific has opened a 375,000-square-foot, carbon-neutral site in Mebane, N.C., designed to produce 40 ...

Johnson & Johnson announces a $2 billion North Carolina manufacturing expansion as part of a broader U.S. onshore ...

Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...

European stocks fell Thursday as investors weighed ongoing concerns about the artificial-intelligence boom and data showing gains in business activity. The composite purchasing managers' index for the ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for the long term. In a report released on August 13, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly and ...